VistaGen Therapeutics (VTGN) Q3 2025 earnings summary

Executive summary

• Advanced clinical-stage neuroscience programs, focusing on intranasal pherine product candidates for rapid, non-systemic therapeutic effects in social anxiety disorder (SAD), major depressive disorder (MDD), menopausal hot flashes, and cancer cachexia.

• Lead asset fasedienol is in registration-directed Phase 3 trials (PALISADE-3 and PALISADE-4) for acute treatment of SAD, with Fast Track designation and top-line results expected in 2025.

• Pipeline includes itruvone (MDD), PH80 (menopausal hot flashes), PH284 (cancer cachexia), and AV-101 (neuropathic pain and Parkinson’s-related dyskinesia), all advancing in clinical or preclinical development.

• Positive exploratory Phase 2A results reported for PH284 in cancer cachexia, expanding the clinical-stage pipeline.

• The company has not achieved revenue-generating status from product sales and expects continued operating losses as development progresses.

Financial highlights

• Research and development expenses rose to $11.3 million for the quarter and $29.2 million for the nine months ended December 31, 2024, up significantly year-over-year due to increased clinical activity and headcount.

• General and administrative expenses were $4.0 million for the quarter and $12.8 million for the nine months, both up year-over-year.

• Net loss attributable to common stockholders was $14.1 million for the quarter and $37.8 million for the nine months, both more than doubling year-over-year.

• Cash, cash equivalents, and marketable securities totaled $88.6 million as of December 31, 2024, expected to fund operations for over a year.

• Revenue for the quarter was $234,000, down from $411,000 year-over-year, primarily from sublicense and collaboration agreements.

Outlook and guidance

• Confident in delivering PALISADE-3 and PALISADE-4 data in 2025, with no anticipated delays and multiple clinical milestones expected.

• Ongoing enhancements in clinical trial execution and increased internal oversight are expected to improve study quality.

• Current cash resources are expected to fund planned operations for more than twelve months from the financial statement issuance date.

• Expects to submit IND for PH80 and advance itruvone to Phase 2B for MDD.

• Anticipates continued operating losses and negative cash flows as clinical pipeline advances.